Tests a score for telling endometriosis from ovarian cancer
Tests a diagnostic score in adults with endometriosis or endometriosis-associated ovarian cancer.
Plain-language title generated from the registry record
Registry title: A Study Evaluating the Diagnostic Performance of OCS in the Differential Diagnosis of Endometriosis vs. Endometriosis-Associated Ovarian Cancer
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 80 with a first diagnosis of endometriosis or endometriosis-associated ovarian cancer who need surgery. It tests whether a blood test can tell the two apart.
- Age
- 18 to 80 years
- Sex
- Women only
- Disease stage
- First diagnosis of endometriosis or endometriosis-associated ovarian cancer, based on symptoms and imaging (transvaginal ultrasound and MRI), with a reason for surgery.
- Earlier treatment
- No earlier surgery with ovarian tissue test results. No chemotherapy or pelvic radiotherapy in the 6 months before the blood sample is taken.
- Biomarker or test result
- Enough blood sample for serum marker testing.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Earlier surgery with ovarian tissue test results available
- Ovarian cancer that has come back
- Another primary cancer at the same time
- Cannot have surgery, or ovarian tissue results cannot be obtained
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07029659, who can take part
Where in China
- Peking Union Medical College Hospital (PuMCH), Chinese Academy of Medical SciencesBeijing, ChinaContact: Peng Peng Associate ProfessorNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07029659
- Record updated
- 19 June 2025
- Original description
Prospectively enroll patients with endometriosis and EAOC who complete the routine diagnostic and treatment process and consent to surgical intervention for OCS testing. Using postoperative ovarian pathological diagnosis as the gold standard, evaluate the clinical diagnostic performance of exosome detection in differentiating between endometriosis and EAOC.Read full original descriptionShow less
A Study Evaluating the Diagnostic Performance of OCS in the Differential Diagnosis of Endometriosis vs. Endometriosis-Associated Ovarian Cancer
Prospectively enroll patients with endometriosis and EAOC who complete the routine diagnostic and treatment process and consent to surgical intervention for OCS testing. Using postoperative ovarian pathological diagnosis as the gold standard, evaluate the clinical diagnostic performance of exosome detection in differentiating between endometriosis and EAOC.
Inclusion: (1) Females aged ≥18 years; (2) Initial diagnosis of endometriosis or EAOC based on clinical presentation and imaging findings (including transvaginal ultrasound and MRI), with surgical indications; (3) Consent to surgical treatment and availability of postoperative ovarian pathological diagnosis; (4) Sufficient specimens for serum marker testing; (5) Voluntary participation in this study with signed informed consent form.
Exclusion: (1) Pregnant and lactating women; (2) Patients who have previously undergone surgery with available ovarian histopathological examination results; (3) Confirmed cases of recurrent ovarian carcinoma; (4) Patients receiving chemotherapy or pelvic radiotherapy within 6 months prior to sample collection; (5) Concurrent primary malignancies; (6) Contraindications to surgical evaluation or inability to obtain ovarian surgical pathology information; (7) Specimens non-conforming to collection/preservation requirements, or contaminated/suspected contaminated samples.